CYP17A1 rs121908079: Understanding 17-Alpha-Hydroxylase Deficiency
The rs121908079 variant is a rare genetic change located within the CYP17A1 gene. It is associated with 17-alpha-hydroxylase deficiency, a condition that disrupts the production of essential steroid hormones, including sex hormones and cortisol.
What each genotype means
Typical enzyme activity
This genotype represents the common, functional version of the CYP17A1 gene. Individuals with this profile typically produce the enzyme necessary for normal adrenal and gonadal steroid synthesis.
This is the most common genotype found in the general population.
Carrier of variant
This genotype indicates you carry one copy of a pathogenic variant in the CYP17A1 gene. Because this condition is inherited in an autosomal recessive manner, carriers typically do not exhibit symptoms of 17-alpha-hydroxylase deficiency, but they may pass the variant to their children.
The frequency of this carrier state is rare and varies significantly by ancestry.
Potential enzyme deficiency
This genotype indicates the presence of two copies of a pathogenic variant, which is associated with 17-alpha-hydroxylase/17,20-lyase deficiency. This condition can lead to clinical features such as hypertension, hypokalemia, and disorders of sexual development due to impaired steroid hormone production. Please discuss these findings with a medical geneticist or endocrinologist for clinical evaluation.
This genotype is extremely rare in the general population.
What is the rs121908079 Variant?
The rs121908079 variant is a specific change in the DNA sequence of the CYP17A1 gene, which is located on chromosome 10. In genetics, a variant like this represents a difference in the building blocks of DNA compared to the most common sequence found in the general population. Because the CYP17A1 gene provides the blueprint for an enzyme critical to hormone synthesis, changes in this region can alter how that enzyme functions. This specific variant is categorized as pathogenic, meaning it is known to disrupt the normal biological processes governed by the gene. It is inherited in an autosomal recessive pattern, which means that an individual typically needs to inherit two copies of the variant—one from each parent—to potentially experience the associated health effects. Understanding where this variant sits on the gene helps researchers predict how it might interfere with the production of the P450c17 enzyme.
The Role of the CYP17A1 Gene
The CYP17A1 gene is responsible for producing an enzyme called cytochrome P450 17A1. This enzyme is a vital player in the body's steroid hormone production line, which takes place primarily in the adrenal glands and the gonads. The enzyme performs two distinct chemical reactions: 17-alpha-hydroxylase activity and 17,20-lyase activity. These reactions are essential steps in converting precursor molecules into active hormones, including cortisol, which helps regulate blood sugar and stress responses, and sex hormones like testosterone and estrogen, which are necessary for reproductive development. When the CYP17A1 gene is altered by a pathogenic variant, the resulting enzyme may be unable to perform these reactions efficiently. This leads to a deficiency in the hormones that the body relies on for maintaining salt balance, blood pressure, and normal sexual maturation, resulting in the clinical features often described as congenital adrenal hyperplasia.
Research and Clinical Associations
Scientific research has established a strong link between pathogenic variants in the CYP17A1 gene and 17-alpha-hydroxylase deficiency. This condition is characterized by a complex set of symptoms, including high blood pressure (hypertension), low potassium levels (hypokalemia), and differences in sexual development. Because the enzyme is required for both cortisol and sex hormone production, its absence or dysfunction creates a hormonal imbalance. The severity of the condition can vary significantly between individuals, even among those who carry the same genetic variants. Some individuals may present with complete deficiency, while others experience partial deficiency, leading to a wide spectrum of clinical presentations. Current evidence classifies this as a rare disorder, and researchers continue to study how different mutations affect the two distinct enzymatic functions of the protein. It is important to note that clinical diagnosis is based on hormone testing and physical evaluation, not just genetic findings.
Population Frequency and Prevalence
The rs121908079 variant is considered rare in the general population. Because it is an autosomal recessive condition, the prevalence of the disorder is low, typically appearing in a small percentage of congenital adrenal hyperplasia cases worldwide. Genetic databases indicate that such pathogenic variants are not common in the general public, and their frequency can vary significantly depending on ancestral background and regional genetic history. Because the variant is rare, most individuals do not carry it. In populations where consanguinity (marriage between close relatives) is more common, the likelihood of inheriting two copies of a rare recessive variant may be higher. Genetic counselors often use this information to help families understand the risk of passing the variant to future generations. If you have concerns about your genetic status or family history, it is recommended to consult with a medical geneticist or a qualified healthcare provider.
Managing Genetic Information
Learning about a genetic variant like rs121908079 can be a significant experience, but it is important to understand what this information means for your health. A genetic result is not a medical diagnosis; it is a piece of data that must be interpreted by a professional in the context of your overall health, symptoms, and family history. If you have received information about this variant, you should discuss it with your clinician or a genetic counselor who can provide context based on your specific situation. They can help you understand the implications of the result and whether any further testing or monitoring is appropriate. You should never make changes to your medical care or medication regimen based solely on a genetic report without consulting your doctor. Genetic information is a tool for informed conversation with your healthcare team, not a substitute for professional medical advice.
How common is this variant?
The rs121908079 variant is a rare autosomal recessive pathogenic variant, meaning it is found at very low frequencies in the general population.
Frequently asked questions
What is 17-alpha-hydroxylase deficiency?
It is a rare form of congenital adrenal hyperplasia caused by mutations in the CYP17A1 gene. It leads to an imbalance of hormones, often resulting in high blood pressure and differences in sexual development.
Is rs121908079 the only cause of this condition?
No, there are over 150 different mutations in the CYP17A1 gene that have been identified as causes for this deficiency. This variant is just one of many possible genetic changes.
Can I be tested for this variant?
Yes, molecular genetic testing for the CYP17A1 gene is available. You should speak with a healthcare provider or genetic counselor to determine if testing is appropriate for you.
What should I do if I am a carrier?
Being a carrier means you have one copy of the variant and typically do not have the condition. You may want to discuss family planning and the risk of passing the variant to children with a genetic counselor.
Sources & further reading
Educational information only, last refreshed 9/23/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908079?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP17A1
Promoter polymorphism in CYP17A1 associated with altered androgen biosynthesis, hormone-sensitive cancer risk, and response to aromatase inhibitors and taxane-based chemotherapy.
This variant is associated with an increased susceptibility to aggressive forms of prostate cancer.
Loss-of-function mutation in CYP17A1 associated with combined 17-alpha-hydroxylase/17,20-lyase deficiency and primary amenorrhea.
Pathogenic nucleotide change in CYP17A1 disrupting sex steroid synthesis, causing amenorrhea and hypertension in adolescent females.